2022
765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D
2021
Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D)
Brown S, Levy C, Hirsch I, Bode B, Carlson A, Shah V, Pinsker J, Weinstock R, Bhargava A, Mehta S, Laffel L, Jones T, Sherr J, Aleppo G, Forlenza G, Ly T. Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D). Journal Of The Endocrine Society 2021, 5: a671-a672. DOI: 10.1210/jendso/bvab048.1370.Peer-Reviewed Original ResearchStandard therapyType 1 diabetesDiabetic ketoacidosisSevere hypoglycemiaInsulin delivery systemsPivotal studiesLarge cohortTarget rangeEpisodes of DKAEpisodes of SHExtension phaseMultiple daily injectionsBurden of diseaseEnd of studyHours/dayMonths of useEffectiveness endpointBaseline A1CHybrid closed-loop systemPrevious therapyPrior therapyT1D durationGlucose targetsInsulin needsDaily injections